An optimized method for high-titer lentivirus preparations without ultracentrifugation

被引:104
作者
Jiang, Wei [1 ,2 ]
Hua, Rui [1 ,2 ]
Wei, Mengping [1 ,2 ]
Li, Chenhong [2 ]
Qiu, Zilong [3 ]
Yang, Xiaofei [2 ]
Zhang, Chen [1 ]
机构
[1] Peking Univ, Sch Life Sci, State Key Lab Membrane Biol, PKU IDG McGovern Inst Brain Res, Beijing 100871, Peoples R China
[2] South Cent Univ Nationalities, Key Lab Cognit Sci, Lab Membrane Ion Channels & Med, Wuhan 430074, Peoples R China
[3] Chinese Acad Sci, Inst Neurosci, Lab Mol Basis Neural Plast, Shanghai 200031, Peoples R China
基金
美国国家科学基金会;
关键词
GENE DELIVERY; VECTOR PREPARATIONS; PURIFICATION; TRANSDUCTION; TITRATION; SYSTEM; HIV-1;
D O I
10.1038/srep13875
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lentiviral technology has proven to be a powerful tool to express exogenous genes in dividing and non-dividing cells. Currently, most protocols for generating high-titer lentivirus require ultracentrifugation, which can be an instrumental barrier for routine operations in a laboratory. In this study, the effect of relative centrifugal force (RCF) on the concentration efficiency of the lentivirus was systematically explored, and it was found that sucrose gradient centrifugation with a relatively low speed (<= 10,000 g) robustly produces a high-titer virus (up to 2 x 10(8) TU/ml). The optimal sucrose concentration is 10%, and the recovery rate of the functional virus is greater than 80%. The infection efficiency of both concentrated and un-concentrated lentivirus decreases rapidly when the viruses are stored at 4 degrees C (tau approximate to 1.3 days) or subjected to multiple freeze-thaw cycles (tau = 1.1 rounds). In summary, we describe an efficient and easy-to-handle protocol for high-titer lentivirus purification.
引用
收藏
页数:9
相关论文
共 29 条
[1]   Optimized production and concentration of lentiviral vectors containing large inserts [J].
Al Yacoub, Nadya ;
Romanowska, Malgorzata ;
Haritonova, Natalie ;
Foerster, John .
JOURNAL OF GENE MEDICINE, 2007, 9 (07) :579-584
[2]  
Aurélie D, 2013, CURR DRUG TARGETS, V14, P1336
[3]  
Azzouz M, 2004, CURR GENE THER, V4, P277
[4]   Lentiviral Vector-Mediated Gene Transfer and RNA Silencing Technology in Neuronal Dysfunctions [J].
Dreyer, Jean-Luc .
MOLECULAR BIOTECHNOLOGY, 2011, 47 (02) :169-187
[5]   A third-generation lentivirus vector with a conditional packaging system [J].
Dull, T ;
Zufferey, R ;
Kelly, M ;
Mandel, RJ ;
Nguyen, M ;
Trono, D ;
Naldini, L .
JOURNAL OF VIROLOGY, 1998, 72 (11) :8463-8471
[6]  
Kafri T, 2001, CURR OPIN MOL THER, V3, P316
[7]   A new improved method for the concentration of HIV-1 infective particles [J].
Kohno, T ;
Mohan, S ;
Goto, T ;
Morita, C ;
Nakano, T ;
Hong, W ;
Sangco, JCE ;
Morimatsu, S ;
Sano, K .
JOURNAL OF VIROLOGICAL METHODS, 2002, 106 (02) :167-173
[8]   Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications [J].
Kumar, Pankaj ;
Woon-Khiong, Chan .
CURRENT GENE THERAPY, 2011, 11 (02) :144-153
[9]   Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors [J].
Kutner, Robert H. ;
Zhang, Xian-Yang ;
Reiser, Jakob .
NATURE PROTOCOLS, 2009, 4 (04) :495-505
[10]  
Matsuoka H, 1998, INT J HEMATOL, V67, P267